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Abstract
Objective: Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection has been proved to be a growing
public health concern. The prevalence and genotypic pattern vary with geographic locations. Limited information is
available to date with regard to HCV genotype and its clinical implications among those former commercial blood donor
communities. The aims of this study were to genetically define the HCV genotype and associated clinical characteristics of
HIV/HCV co-infected patients from a region with commercial blood donation history in central China.
Methods: A cross sectional study, including 164 HIV infected subjects, was conducted in Shanxi province central China.
Serum samples were collected and HCV antibody testing, AST and ALT testing were performed. Seropositive samples were
further subjected to RT-PCR followed by direct sequence coupled with phylogenetic analysis of Core-E1 and NS5B regions
performed in comparison with known reference genotypes.
Findings: A total of 139 subjects were HCV antibody positive. Genotype could be determined for 88 isolates. Phylogenetic
analysis revealed that the predominant circulating subtype was HCV 1b (65.9%), followed by HCV 2a (34.1%). The HCV viral
load in the subjects infected with HIV1b was significantly higher than those infected with HCV 2a (P=0.006). No significant
difference for HCV RNA level was detected between ART status, CD4+ cell count level and HIV RNA level. Serum AST and ALT
level were likely to increase with HCV RNA level, although no significance was observed. Those who had conducted
commercial donation later than 1991 (OR 3.43, 95% CI: 1.12–10.48) and had a short duration of donation (OR 0.35, 95% CI:
0.13–0.96) were more likely to be infected with HCV 1b.
Conclusion: These results suggest that HCV subtype 1b predominates in this population, and the impact of HIV status and
ART on HCV disease progression is not significantly correlated.
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Introduction
Hepatitis C virus (HCV) was first identified in 1989 as the
principal cause of post transfusion of non-A non-B hepatitis [1].
About 3% of the world population is infected with HCV, with a
total of about 170 million carriers. Due to shared risk factors for
transmission, co-infection with HIV and HCV is common [2].
Unregulated commercial blood collection among farmers occurred
in central China, including Henan, Anhui and Shanxi provinces,
during the 1990s resulting in the second major epidemic of HIV in
the country. Previous studies have indicated that co-infection of
HIV and HCV is very common in former blood donors [3,4]. The
first outbreak of HCV infection among plasma donors in China
was reported in the last century [5], and since then the issue of
HIV co-infection with HCV have been studied extensively, with
most of the studies demonstrating high seroprevalence of HCV in
this former commercial blood donors society [6,7,8,9].
Understanding HIV/HCV co-infection and their clinical
characteristics is of significant public health importance. Co-
infection with HIV and HCV has been shown to increase HCV
viral loads and may accelerate the natural course of chronic
hepatitis C infection, increase the risk for the development of
cirrhosis, hepatocellular carcinoma (HCC), and results in hasten-
ing progression to end-stage liver disease (ESLD)
[10,11,12,13,14,15], although whether co-infection HIV and
HCV results in a faster progression to AIDS remains controversial
[16,17]. Unfortunately, such studies have rarely been done in
China. Furthermore, combined intervention and treatment for
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been rarely addressed.
HCV is a genetically diverse RNA virus with a single strand,
positive sense genome, and is classified into 6 major genotypes
with closely related isolates being grouped into subtypes [18,19].
To date, genotypes 1, 2 and 3 have a worldwide distribution, while
other genotypes have been found in more restricted regions only
[20]. Genotyping is an important tool for epidemiologic studies,
since HCV genotypes may vary according to epidemic history in
different geographic regions with different genotypes manifesting
substantial differences in clinical characteristics, such as response
to treatment, which is of central importance in disease treatment
and prevention. In China, the existing literature suggests that the
prevalence of HCV genotype is highly heterogeneous with regard
to infection sources and epidemic region. Over the years, despite
the widespread evidence of co-infection with HIV and HCV,
clinical characteristics of HCV/HIV co-infection in China has
rarely specifically addressed, especially in terms of the association
between HCV genotypes and clinical characteristics.
Therefore, a cross sectional study was designed and conducted
to determine the prevalence of HCV genotypes within a sample of
HIV infected patients from a rural Chinese community and to
examine correlations between genotypes and the clinical implica-
tions, such as HCV RNA viral load distribution and serum
enzyme levels, of these HCV/HIV co-infected patients. Our
observations could bring new insight into the management of
HIV/AIDS patients to reduce their morbidity and mortality.
Material and Methods
Ethics Statement
This study was approved by the Institutional Review Board of
Fudan University, China. Written consent was obtained from all
the adult participants before any procedures were performed.
Interview data did not bear the names of respondents and all data
were anonymized before analysis.
Study sites and participants
The present study was conducted in a county in the southern
part of Shanxi province in central China, which was once reported
to have a high prevalence rate of HIV attributed to former
commercial blood donors [7,21], and harbors a large number of
former commercial blood donors attributed to the establishment of
an commercial blood donation center in 1995.
A total number of 164 HIV positive subjects who have been
registered to the National HIV/AIDS Information System were
randomly selected into the present study. Data for participants’
socio-demographic characteristics and HIV transmission modes
were extracted from the National HIV/AIDS Information System
using a standard questionnaire form. Free antiretroviral treatment
(ART) has been available for HIV/AIDS patients since 2003 in
the study area.
Serological testing
HCV serology. ELISA for Anti-HCV immunoglobulin G
(IgG) antibody was tested to determine HCV infection status
according to the manufacturer’s protocol (Wantai Biomedical,
Beijing, China). All the sera samples were assayed blindly in
duplicate. Serum alanine aminotransferase (ALT) and aspartate
aminotransferase (AST) were evaluated with commercial reagent
kits (Shanghai Kehua Bioengineering Co. Ltd., China). Normal
values were considered as: 10–40 IU/L for AST, and 5–40 IU/L
for ALT.
HCV RNA extraction
HCV-RNA extraction was carried out from 200 ml of serum
using QIAamp1 Viral RNA Kit (QIAGEN, Valencia, CA),
following the manufacturer’s instructions. The synthesis of the
complementary DNA (cDNA) was done immediately after RNA
extraction and store 280uC. To avoid false-positive results,
rigorous procedures proposed for nucleic acid amplification
diagnostic techniques were followed.
Complimentary DNA (cDNA) synthesis
Reverse transcriptase reaction was performed using the
Moloney Murine Leukemia Virus Reverse Transcriptase
(MMLV-RT) and random primers. The final volume of the
reaction was 60 ml in the following concentrations: 50 mM Tris–
HCl (pH 8.3), 75 mM KCl, 3 mM MgCl2, 10 mM DTT,
0.5 mM of each dNTP, 450 ng random primers, 30URNAse
enzyme inhibitor (RNase OUTTM), and 300 U MMLV-RT.
Samples were submitted to the following temperature cycles: 70uC
for 10 min, 25uC for 15 min, 37uC for 60 min, and 95uC for
15 min in a thermocycler (Eppendorf Mastercycler 1, Eppendorf,
Hamburg, Germany).
Amplification & Sequencing of HCV NS5B, C/E1 region
Polymerase chain reaction (PCR). Polymerase chain reac-
tions (PCR) were done in two stages to increase sensitivity. HCV
NS5B and C/E1 were amplified for genotyping and sequence
analysis. Specific primers used for amplification and amplification
cycles were as described [22]. The final PCR amplicons were
separated by agarose gel electrophoresis, the correct bands were
excised from agarose gel and extracted using the GFXTM PCR
DNA and Gel Band purification kit (Amersham Bioscience UK
Limited, Little Chalfont, United Kingdom). The second round
PCR primers were used for the direct sequencing reactions using
BigdyeH Terminator v3.1 Cycle Sequencing kit (Applied Biosys-
tems, Foster City, CA) following the manufacturer’s protocol. The
resulting sequence data were checked by hand.
Quantification of HCV RNA
serum HCV viral load was determined by using the one-step
quantitative HCV RT-PCR kit (Shenzhen Piji Co. Ltd., China)
with the standard-curve Taqman probe method. All tests were
performed according to the manufacture protocol. (Piji Bio-Tech
Company, Shenzhen., China)
Phylogenetic Analysis
Sequence alignments were created using MUSCLE and
manually edited [24]. Sequences were then classified into
phylogenetic groups (i.e. genotypes and subtypes) using the REGA
HCV subtyping tool (version 2.0, available at: www.bioafrica.net)
[23]. In addition, maximum likelihood phylogenies were con-
structed using PhyML with reference strains obtained from the
HCV sequence database (http://hcv.lanl.gov/content/hcv-db/
index) provided by the Los Alamos National Laboratory with the
following accession numbers: 1a.US.H77.NC_004102,
1a.US.HCV-H.M67463, 1a.US5003.EF407419, 1a.LTD6-2-
XF224.AF511950, 1b.BR.03.EF032892, 1b.CNAY587016.AY5
87016, 1b.JPJT.D11355, 1c.IDHC-G9.D14853, 1c.INAY051292.
AY051292, 1g.ES1804.AM910652, 2a.JPAY746460.AY746460,
2a.JPHC-J6.D00944, 2a.JPJFH-1.AB047639, 2b.JPHC-J8.D109
88, 2b.JPUT971017.AB030907, 2b.MD2B-1.AF238486, 2c.BEBE1.
D50409, 2i.VND54.DQ155561, 2j.VE.05.HM777359, 2j.VE.06.
HM777358, 2k.MDVAT96.AB031663, 3a.DEHCVCENS1.X76
918, 3a.CB.AF046866, 3a.NZL1.NC_009824, 3b.JPHCV-Tr.
HCV/HIV Coinfections in China
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Y11604, 4a.USF7157.DQ418788, 4b.CAQC264.FJ462435, 4b.
PTP026.FJ025854, 4b.PTP212.FJ025855, 4b.PTP245.FJ025856, 4c.
CAQC381.FJ462436, 4d.CAQC382.FJ462437, 4d.ES24.DQ5160
83, 4d.US03-18.DQ418786, 4d.PS2.EU392172, 4f.FRIFBT84.
EF589160, 4f.FRIFBT88.EF589161, 4f.CM_DAV9905.EU392169,
4f.CM_SP1578.EU392170, 4f.PS4.EU392174, 4f.PS6.EU392175,
4g.CAQC193.FJ462432, 4k.CAQC383.FJ462438, 4k.PB65185.EU
392171, 4k.PS3.EU392173, 4l.CAQC274.FJ839870, 4m.CAQC
249.FJ462433, 4n.CAQC97.FJ462441, 4o.CAQC93.FJ462440, 4p.
CAQC139.FJ462431, 4q.CAQC262.FJ462434, 4r.CAQC384.
FJ462439, 4t.CAQC155.FJ839869, 5a.GBEUH1480.NC_009826,
5a.ZASA13.AF064490, 6.CNGZ52557.DQ278892, 6a.HK6a35.
DQ480513, 6b.Th580.NC_009827, 6c.THTh846.EF424629, 6d.
VNVN235.D84263, 6e.CNGX004.DQ314805, 6f.THC-0044.D
Q835760, 6g.HKHK6554.DQ314806, 6h.VNVN004.D84265, 6i.
THC-0159.DQ835762, 6j.THC-0667.DQ835761, 6k.CNKM45.
DQ278891, 6l.VND33.EU246933, 6m.THC-0185.DQ835765, 6n.
CNKM42.AY878652, 6o.VND85.EU246934, 6p.CAQC216.EF
424626, 6q.CAQC99.EF424625, 6r.CAQC245.EU408328, 6s.CA
QC66.EU408329, 6t.VND49.EU246939, 6u.CNDH012.EU40
8330, 6v.CN.NK46.EU158186, 6w.TWHCV-6-D140.EU643834,
7a.CAQC69.EF108306.
Statistical analysis
Original questionnaire data and laboratory results were entered
and managed with EpiData 3.0 and then transferred to SAS v8.2
(SAS institute Inc., Cary, North Carolina, USA) for further
analysis. Descriptive statistics and univariate analysis were
performed to examine the correlates of HCV seropositivity.
Multiple logistic regression analyses were conducted to identify
potential factors associated with HCV subtype 1b infection
compared to those with HCV subtype 2a infection. Crude odds
ratio and odds ratio adjusted for gender and age group were
generated to determine whether a variable was associated with
HCV infection. All p-values #0.05 were considered to be
statistically significant.
Results
Sociodemographic Characteristics of Study Participants
A total of 164 HIV positive subjects were finally recruited into
the present study. Of them, 139 (84.7%) were HCV/HIV co-
infected while 25 (15.3%) were HIV mono-infected (Table 1).
Among the study subjects, those who participated in HCV/HIV
co-infected group were more likely to be male (P=0.019) and
older (P=0.013) (Table 1). No significant differences were
reported between the co-infected and mono-infected groups in
martial status, education, family income, smoking habits or
consumption of alcohol. Eighty-six per cent of all participants
acquired HIV from commercial blood donation while in the HIV
mono-infected group transmission of HIV was more likely to occur
from blood transfusion and sexual contact (24% vs. 3.6% for
transfusion and 28% vs. 2.2% for sexual transmission). In addition
approximately 78.7% of all study participants had received ART.
The major demographic characteristics of all participants are
summarized in Table 1.
Hepatitis C Virus Sequence Amplification and
Classification
Of the 139 HCV seropositive patients included in this study, 88
were also positive for HCV RNA. NS5B and C/E1 sequences
were successfully amplified from 84 and 87 participants, respec-
tively. HCV genotypes were determined using the REGA HCV
Subtyping tool (version 2), which uses phylogenetic methods to
identify the subtype against a panel of HCV subtype reference
sequences. HCV genotyping was determined for the NS5B gene
Table 1. Socio demographic characteristics of HIV mono-
infected and HIV/HCV co-infected subjects in the study.
Characteristics HIV HIV/HCV Total
N=25 N=139 N=164
No. (%) No. (%) No. (%)
Gender (P=0.019)
Male 11 (44.0) 95 (68.3) 106 (64.6)
Female 14 (56.0) 44 (31.7) 58 (35.4)
Age group (P=0.013)
#20 2 (8.0) 1 (0.7) 3 (1.8)
21–49 20 (80.0) 98 (70.5) 118 (72.0)
$50 3 (12.0) 40 (28.8) 43 (26.2)
Marital status (P=0.147)
Single 4 (16.0) 10 (7.2) 14 (8.5)
Ever married 21 (84.0) 129 (92.8) 150 (91.5)
Education (P=0.460)
Illiterate 2 (8.0) 13 (9.4) 15 (9.1)
Primary school 10 (40.0) 54 (36.8) 64 (39.0)
Middle school 10 (40.0) 66 (47.5) 76 (46.3)
Senior middle 3 (12.0) 5 (4.3) 9 (5.5)
Family income (P=0.830)
,1000 17 (68.0) 83 (59.7) 100 (61.0)
1001,2000 3 (12.0) 20 (14.4) 23 (14.0)
2001,3000 2 (8.0) 10 (7.2) 12 (7.3)
.3001 3 (12.0) 26 (18.7) 29 (17.7)
Alcoholic Drink (P=0.329)
Yes 3 (12.0) 9 (6.5) 12 (7.3)
No 22 (88.0) 130 (93.5) 152 (92.7)
Smoking (P=0.152)
Yes 8 (32.0) 66 (47.5) 74 (45.1)
No 17 (68.0) 73 (52.5) 90 (54.9)
Routes of HIV
transmission (P,0.001)
Commercial blood
donation
13 (52.0) 126 (90.6) 139 (84.8)
Transfusion 4 (16.0) 6 (4.3) 10 (6.1)
Sexual transmitted 7 (28.0) 7 (5.0) 14 (6.1)
Mother to Child 1 (4.0) 0 (0.0) 1 (0.6)
Antiretroviral therapy
(P=0.052)
Yes 16 (64.0) 113 (81.3) 129 (78.7)
No 9 (36.0) 26 (18.7) 35 (21.3)
CD4+ counts (P=0.569)
,200 7 (28.0) 47 (33.8) 54 (32.9)
$200 18 (72.0) 92 (66.2) 110 (67.1)
HIV viral load (P=0.946)
,1000 7 (28.0) 38 (27.3) 45 (27.4)
$1000 18 (72.0) 101 (72.7) 119 (72.6)
doi:10.1371/journal.pone.0094219.t001
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found to be infected with genotype 2a (Figure 1). ML phylogenetic
analysis also demonstrates significant clustering with high boot-
strap supports (100%) for sequences belonging to the genotypes 1b
and 2a clades respectively. REGA subtyping confirmed this
observation for the C/E1 region with 57 patients infected with 1b
and 30 infected with 2a. In addition, a similar phylogenetic pattern
was observed for the C/E1 region with significant bootstrap
support values (data not shown). No other genotypes were detected
in this study. The genotyping results were consistent when
analyzed with either NS5B or C/E1 region (measurement of
agreement Kappa=0.881, P,0.001).
HCV viral load distribution
Among those HCV RNA positive subjects, HCV viral loads
were determined and compared. The overall median HCV viral
load was 5.84log10copies/ml (interquartile range (IQR), 5.12–6.94
log10copies/ml). Furthermore, HCV viral load differences be-
tween genotypes, ART status, HIV viral load and CD4+count
were explored. No significant differences were observed between
the ART group (median 4.59 log10copies/ml; IQR, 0.95–5.89
log10copies/ml) and the ART naı ¨ve group (median 5.31
log10copies/ml; IQR, 0.95–6.06 log10copies/ml) (P=0.429)
(Figure 2). Similarly, HCV viral load was not significantly different
between the HIV viral loads #1000 copies/ml group and HIV
viral loads .1000 copies/ml group (P=0.520) and low CD4
count group and high CD4 high counts group (P=0.935).
However, the HCV viral load of subtype 1b subjects (median
6.03 log10copies/ml; IQR, 5.50–6.56 log10copies/ml) was signif-
icantly higher than subtype 2a subjects (median 5.43; IQR, 4.87–
5.93 log10copies/ml) (P=0.006) (Figure 2).
Relationship between HCV genotype and serum enzyme
level
The serum AST and ALT levels were further analyzed for HCV
genotypes 1b and 2a. The mean of AST and ALT were 36.72 UI/
L and 47.21 UI/L for subtype 1b subjects, whereas the means of
AST and ALT were 32.86 UI/L and 35.26 UI/L for subtype 2a
subjects. As shown in Figure 3A and 3B, abnormal AST and ALT
level (normal range 5–40 UI/L) were detected among 32.8% (19/
Figure 1. Maximum-Likelihood phylogeny estimated from NS5B sequences (H77 positions 8261–8639). Bootstrap support values are
only shown for the major ancestral nodes of interest. Reference HCV sequences are indicated by genotype followed by their Genbank accession
numbers. Similar phylogenetic patterns were observed for C/E1 (not shown).
doi:10.1371/journal.pone.0094219.g001
Figure 2. Box and Whisker Plots of HCV viral load distribution by related factors. (A) HCV viral load stratified by subtype 1b and 2a. (B)
HCV viral load between ART naı ¨ve and ART treated subjects. (C) Distribution of HCV viral load by HIV viral load ,1000 and .1000. (D) HCV viral load
between CD4 counts ,200 and CD4 counts .200.
doi:10.1371/journal.pone.0094219.g002
HCV/HIV Coinfections in China
PLOS ONE | www.plosone.org 5 April 2014 | Volume 9 | Issue 4 | e9421958) and 41.4% (24/58) HCV subtype 1b infected subjects, with
ALT were significantly increased with HCV viral load
(PAST=0.216, PALT=0.015). Similarly, serum AST and ALT
level in the HCV subtype 2a infected subjects tended to be
increased with HCV viral load though statistical significance was
not observed (PAST=0.557 and PALT=0.229), and the abnormal
AST and ALT level frequency among subtype 2a subjects were
26.7% (8/30) and 23.3% (7/30), respectively.
Figure 3. Correlation of serum enzyme levels and HCV viral load. (A) Association of AST and HCV viral load in subjects infected with subtype
1b. (B) Association of ALT and HCV viral load in subjects infected with subtype 1b. (C) Association of AST and HCV viral load in subjects infected with
subtype 2a. (D) Association of ALT and HCV viral load in subjects infected with subtype 2a.
doi:10.1371/journal.pone.0094219.g003
Table 2. Multivariate Logistic regression analysis of potential factors associated with HCV subtype 1b infection, compared to those
with HCV subtype 2a infection (n=88).
Characteristics/Risk factor Subtype 2a (N=30) Subtype 1b (N=58)
N (%) N (%) COR (95%CI) AOR* (95%CI)
First blood donation time
#
,1990 10 (34.5) 7 (12.5) 1.00
$1991 19 (65.5) 49 (87.5) 3.68 (1.22–11.08) 3.43 (1.12–10.48)
Duration of commercial donation
#
,3 17 (58.6) 45 (80.4) 1.00
$3 12 (41.4) 11 (19.6) 0.35 (0.13–0.93) 0.35 (0.13–0.96)
Routes of HIV transmission
Commercial blood donation 29 (96.7) 56 (96.6) 1.00
Transfusion 1 (3.3) 2 (3.4) 1.03 (0.09–11.09) 0.92 (0.07–11.03)
#some subject have not donated.
*AOR adjusted for gender and age group.
doi:10.1371/journal.pone.0094219.t002
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infection
Analysis for potential risk factors was restricted to HCV subtype
1b and 2a cases. As shown in table 2, univariate analysis revealed
that first donation time (P=0.020), duration of commercial blood
donation (P=0.036) was significantly associated with subtype 1b
infection. Multivariate Logistic analysis adjusted by age and
gender indicated those who donated blood later than the year
1991 were more likely to be HCV subtype 1b infection
(AOR=3.43, 95% CI: 1.12–10.48), whereas if the duration of
commercial blood donation was more than 3 years then the
participants were less likely to be HCV 1b infection (AOR=0.35,
95% CI: 0.13–0.96). No significant differences were found
between subtype and route of transmission.
Discussion
During the early 1990s, commercial plasma and blood
collection activities were once common in rural areas of central
China and commercial donation for money seemed to be an easy
way for those rural farmers to augment their income at that time
[25]. However, due to the unhygienic process of pooling blood and
the reinfusion of compatible red blood cells to permit more
frequent donations prompted exposing the donors to a range of
pathogens. The nature of such practices led to high HCV
infections rates in blood and plasma donors with enhanced risk of
HIV transmission in addition to other opportunistic infections
[25,26].
Several studies on HCV co-infection in former blood donors
from other areas in China have shown similar results demonstrat-
ing that the HCV prevalence can be as high as 78.6% to 86.3%
among HIV positive subjects [7,8,27]. Our results further confirm
that dual HIV and HCV infection is relatively common. This is of
public health importance, given that HCV co-infection may
complicate, antiretroviral therapy (ART) and the use of the
different regimens should be closely monitored in this former
commercial blood donation region.
To elucidate the epidemiologic picture of circulating viral
strains, HCV NS5B and C/E1, two reliable and most commonly
used regions, were selected as targets to infer the genotype
distribution in the present study [28]. The genotypes from two
assays showed high consistency with no recombination detected.
Overall, genotyping data showed that two main HCV genotypes,
1b and 2a, are circulating within those who are infected with HIV
in central China. These results are in direct agreement with
previous reports on HCV and HIV co-infection among commer-
cial blood donor from neighboring provinces, such as Henan and
Hubei in China [8,29,30]. Actually, subtype 1b and 2a are two of
the most prevalent genotypes in China, with 1b prevailing in
southern China while 2a is more common in northern China [29].
Interestingly, although a similar genotype pattern, consisting of
subtypes 1b and 2a, was observed, the frequency of HCV subtypes
differs across geographic regions. This altered distribution on
genotype frequency may indeed corroborate recent reports that
subtype 2a infections in China have been reduced [31].
The practice of risk behaviors is knowingly an important
determinant of HCV transmission. Since the majority of study
subjects had a history of commercial blood donation, HCV blood
borne transmission should be of importance. In the current study,
HCV 1b infection was associated with first donation time, while an
inverse correlation has been observed from duration of commer-
cial donation. It is speculated that subtype 1b has entered and
become a predominate strain in this population after the year
1991. Conversely, those who had conducted commercial blood
donation earlier (,1990) are more likely to be exposed to HCV
subtype 2a.Moreover, those who and had a long duration of illegal
blood donation often means donated earlier and are tend to be
infected with subtype 2a.
To determine whether the HIV infection and ART affect
nature course of chronic HCV infection, HCV viral load were
compared between HIV RNA level, ART and CD4+ cell level.
Currently, some discrepancy exists with previous data regarding
HIV/HCV co-infection and the impact of ART on HCV
progression [32,33]. Data from the present study indicates that
no significant difference was observed in HCV viral loads when
the comparisons above were taken into account. Conversely, HCV
viral loads were significantly higher in patients infected with
subtype 1b than patients infected with subtype 2a (P=0.006).
There is discrepancy between our results and the studies by Liu et
al. which indicated that patients infected with subtype 1b showed a
lower HCV viral load compared with subtype 2a [30]. However,
in general HCV 1b has been linked to severe chronic liver disease
with results from this study supporting this fact that subtype 1b
might be more aggressive and may be associated with high serum
HCV levels.
Meanwhile, host responses of chronic HCV infection in those
HIV positive subjects, in particular ALT and AST, have also been
explored. Data from current study indicates that the majority of
the HCV infected subjects’ serum AST and ALT level are within
normal range. Moreover, as previously been reported HCV viral
load may not correlate with serum enzyme level in either subtype
[34]. Furthermore, it is unlikely that the measurement of such
enzymes at a single timepoint will be representive of the ALT/
AST profile over time. Therefore, longitudinal data will better aid
in supporting these conclusions.
In conclusion, the present study demonstrates that HCV/HIV
co-infection is common in the former commercial blood donation
community, with HCV 1b and 2a the two predominate subtypes.
Although, HCV viral loads were higher in the subjects infected
with subtype 1b than those who were infected with 2a, there is no
correlation between HIV viral load, ART status, CD4+ cell
counts, and HCV viral levels. Moreover, whether those specific
subtypes could contribute to elevation of AST and ALT levels
remains unclear. Prospective studies on HCV subtypes profile and
clinical manifestation might be helpful in elucidating this
understanding.
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